

"Express Mail" mailing label number EL 856 168 922 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on November 5, 2001.

By: Michelle Stempien Printed: Michelle Stempien

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bailleul, et al.

Title: NOVEL HUMAN LEPTIN RECEPTOR GENE-RELATED PROTEIN

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. §3.73(b),  
REVOCATION OF POWER OF ATTORNEY AND  
APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8179, Frame 0620, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Jenny Buchbinder	Reg. No. 48,588
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Lynn E. Murry	Reg. No. 42,918
Shirley A. Recipon	Reg. No. 47,016
Cathleen M. Rocco	Reg. No. 46,172
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168

**Please direct all correspondence to:**

Legal Department  
Incyte Genomics, Inc.  
3160 Porter Drive  
Palo Alto, California 94304


and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Genomics, Inc.,  
Phone: (650) 845-4639, Fax: (650) 849-8886 or (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: November 5, 2001

By:   
Lee Bendekgey  
VP, General Counsel/Corporate Secretary



PF-0111-1 US

## DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,  
and

I believe that I am an original, first, and joint inventor of the subject matter which is  
claimed and for which a United States patent is sought on the invention entitled

### A NOVEL HUMAN LEPTIN RECEPTOR-RELATED PROTEIN

the specification of which:

☐ is attached hereto.

☒ was filed on April 15, 1997, as application Serial No. 08/843,370, and if this box contains  
an X ☐, was amended on \_\_\_\_\_.


☐ was filed as Patent Cooperation Treaty international application No. \_\_\_\_\_ on  
\_\_\_\_\_, 19\_\_\_\_, if this box contains an X ☐, was amended on under Patent Cooperation Treaty  
Article 19 on \_\_\_\_\_ 19\_\_\_\_, and if this box contains an X ☐, was amended on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified  
specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of  
this application in accordance with Section 1.56(a) of Title 37 of the United States Code.

I hereby claim the benefit under Section 119 of Title 35 of the United States Code of any  
foreign application(s) for patent or inventor's certificate indicated below and of any Patent  
Cooperation Treaty international applications(s) designating at least one country other than the  
United States indicated below and have also identified below any foreign application(s) for  
patent or inventor's certificate and Patent Cooperation Treaty international application(s)  
designating at least one country other than the United States for the same subject matter and  
having a filing date before that of the application for said subject matter the priority of which is  
claimed:

08/843,370



PF-0111-1 US

Country	Number	Filing Date	Priority Claimed
		// Yes // No	
		// Yes // No	

I hereby claim the benefit under Section 119(e) of Title 35 of the United States Code of any United States provisional application(s) listed below.

I hereby claim the benefit under Section 120 of Title 35 of the United States Code of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph, Section 112 of Title 35 of the United States Code, I acknowledge my duty to disclose material information, as defined in Section 1.56(a) of Title 37 of the United States Code, which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application	Status (Pending, Abandoned, Patented)
Serial No. Filed	
08/691,071 August 1, 1996	Pending

I hereby appoint the following:

<b>LUCY J. BILLINGS</b>	<b>Registration No. 36,749</b>
<b>MICHAEL C. CERRONE</b>	<b>Registration No. 39,132</b>
<b>SHEELA MOHAN-PETERSON</b>	<b>Registration No. 41,201</b>
<b>COLETTE C. MUENZEN</b>	<b>Registration No. 39,784</b>
<b>KAREN J. ZELLER</b>	<b>Registration No. 37,071</b>

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

**LUCY J. BILLINGS, ESQ.**  
**INCYTE PHARMACEUTICALS, INC.**  
**3174 PORTER DRIVE, PALO ALTO, CA 94304**

**TEL: 650-845-4170 FAX: 650-845-4166**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.




PF-0111-1 US

**First Joint Inventor:**

Full name:

**BERNARD BAILLEUL**

Signature:

  
\_\_\_\_\_  
Jan 12<sup>th</sup> 1998

Date:

Citizenship:

France

Residence:

Lomme, France


P.O. Address:

4 rue pierre Curie  
59160 Lomme, France**Second Joint Inventor:**

Full name:

**A. DONNY STROSBERG**

Signature:

  
\_\_\_\_\_  
Jan 9 1998

Date:

Citizenship:

~~France~~ Belgium

Residence:

Paris, France


P.O. Address:

66 rue de Javel  
Paris 75015, France**Third Joint Inventor:**

Full name:

**INGRID E. AKERBLOM**

Signature:

  
\_\_\_\_\_  
2/24/98 1998

Date:

Citizenship:

United States of America

Residence:

Redwood City, California

P.O. Address:

1234 Johnson Street  
Redwood City, California 94061